Enochian Biosciences Inc. reported earnings results for the first quarter ended September 30, 2022. For the first quarter, the company reported net loss was USD 7.7 million compared to USD 10.41 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.2 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 USD | +9.09% | +49.47% | -54.26% |
05:32pm | Renovaro, Amsterdam UMC Cancer Center Plan to Form Joint Venture for Cancer Immunotherapy | MT |
03:20pm | Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy | CI |
1st Jan change | Capi. | |
---|---|---|
-54.26% | 19Cr | |
+11.97% | 12TCr | |
+13.11% | 11TCr | |
-9.71% | 2.39TCr | |
-1.69% | 2.16TCr | |
-10.60% | 1.9TCr | |
-41.25% | 1.7TCr | |
-14.20% | 1.63TCr | |
+6.49% | 1.41TCr | |
+30.27% | 1.2TCr |
- Stock Market
- Equities
- RENB Stock
- News Renovaro Inc.
- Enochian Biosciences Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022